TY - JOUR
T1 - A new topical biotechnological phytocomplex for truncal mild-moderate acne restores skin microbiota balance
AU - Guerra-Tapia, Aurora
AU - Martínez, Helena
AU - Nieto, Carlos
AU - Ruiz Alonso, Carlos
AU - Bermejo, Rafael
AU - Carrón, Nerea
AU - Garcia-Segura, Sergio
AU - Gonzalez-Torres, Pedro
AU - Palacios-Martínez, David
AU - Bou, Lola
AU - Pérez, Montse
AU - De Lucas, Raul
N1 - Publisher Copyright:
© 2024 The Author(s). Skin Research and Technology published by John Wiley & Sons Ltd.
PY - 2024/7
Y1 - 2024/7
N2 - Background: The disruption of the microbial community or dysbiosis alters the functional composition, metabolic activity, and local distribution of the microbiota leading the development of acne. The aim of this study is to evaluate the effect of a lotion containing a biotechnological phytocomplex, niacinamide, and succinic acid in the bacterial diversity of subjects with truncal mild-moderate acne and its clinical benefits due to microbiota changes. Materials and Methods: Open, clinical study in 43 subjects with truncal mild-moderate acne treated with a lotion for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated through IGA acne severity scale, biometric measurements, and safety. Results: After 56 days of product's use, an increase in richness alpha diversity was found (p = 0.005), with a decrease in Cutibacterium acnes relative abundance (66.43% vs. 58.11%, p = 0.009). The clinical results showed a decrease in IGA score (27.59% decrease; p = 0.001), the inflammatory lesions (52.12% decrease, p = 0.006) and erythema (18.33% decrease, p = 0.007), and desquamation index (63.83% decrease, p = 0.02). The responder analysis of the IGA score showed that 60.47% of patients improved by at least one point at day 56. The product was well tolerated along the study. Conclusion: The use of the lotion on acneic skin was effective on rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing erythema and desquamation, and improving acne's severity.
AB - Background: The disruption of the microbial community or dysbiosis alters the functional composition, metabolic activity, and local distribution of the microbiota leading the development of acne. The aim of this study is to evaluate the effect of a lotion containing a biotechnological phytocomplex, niacinamide, and succinic acid in the bacterial diversity of subjects with truncal mild-moderate acne and its clinical benefits due to microbiota changes. Materials and Methods: Open, clinical study in 43 subjects with truncal mild-moderate acne treated with a lotion for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated through IGA acne severity scale, biometric measurements, and safety. Results: After 56 days of product's use, an increase in richness alpha diversity was found (p = 0.005), with a decrease in Cutibacterium acnes relative abundance (66.43% vs. 58.11%, p = 0.009). The clinical results showed a decrease in IGA score (27.59% decrease; p = 0.001), the inflammatory lesions (52.12% decrease, p = 0.006) and erythema (18.33% decrease, p = 0.007), and desquamation index (63.83% decrease, p = 0.02). The responder analysis of the IGA score showed that 60.47% of patients improved by at least one point at day 56. The product was well tolerated along the study. Conclusion: The use of the lotion on acneic skin was effective on rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing erythema and desquamation, and improving acne's severity.
KW - acne vulgaris
KW - biofilm
KW - dysbiosis
KW - quorum quenching
KW - quorum sensing
KW - truncal acne
UR - http://www.scopus.com/inward/record.url?scp=85199179118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199179118&partnerID=8YFLogxK
U2 - 10.1111/srt.13806
DO - 10.1111/srt.13806
M3 - Article
C2 - 39044362
AN - SCOPUS:85199179118
SN - 0909-752X
VL - 30
JO - Skin Research and Technology
JF - Skin Research and Technology
IS - 7
M1 - e13806
ER -